Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.12, 2009-12, pp. : 983-989

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incorporating Equity–Efficiency Interactions in Cost-Effectiveness Analysis—Three Approaches Applied to Breast Cancer Control

By Baeten Stefan A. Baltussen Rob M. P. M. Uyl-de Groot Carin A. Bridges John Niessen Louis W.

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 573-579

Blackwell Publishing

Access to resources Recommend Favorite

Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis

By Prica Anca Chan Kelvin Cheung Matthew

Cancer, Vol. 121, Iss. 15, 2015-08 ,pp. : 2637-2645

Blackwell Publishing

Access to resources Recommend Favorite

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine Shabaruddin Fatiha H

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

Estimating `Costs' for Cost-Effectiveness Analysis

By Miners Alec

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 745-751

Adis International

Access to resources Recommend Favorite

Subgroups and Heterogeneity in Cost-Effectiveness Analysis

By Sculpher Mark

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 799-806

Adis International

Access to resources Recommend Favorite